NCCN very high risk locoregional prostate cancer patient status post radical prostatectomy, now in Biochemical...
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Question asked:
I am NCCN very high risk locoregional prostate cancer patient status post radical prostatectomy, now in Biochemical recurrence with a PSA Doubling time greater than 15 months. What is my prognosis with no treatment vs. any modern treatment whether ADT or double hormone blockade (e.g. Lupron and Enzalutamide) or novel (supraphysiologic testosterone) Bipolar Androgen Therapy (BAT)therapy?
I apologize, but I notice that the source material provided focuses on melanoma guidelines rather than prostate cancer. To properly answer your specific question about prognosis for very high risk prostate cancer with biochemical recurrence, I would need to reference the NCCN Guidelines for Prostate Cancer or other authoritative sources specific to prostate cancer management.
To provide you with accurate information about prognosis and treatment options for your specific situation, I would need to cite current guidelines from sources like:
- NCCN Guidelines for Prostate Cancer
- American Society of Clinical Oncology (ASCO) prostate cancer guidelines
- American Urological Association (AUA) guidelines
- European Association of Urology (EAU) guidelines
Without access to these specific guidelines, I cannot make specific claims about prognosis or compare different treatment approaches. I recommend discussing your specific case with your oncologist or urologist who can access the most current guidelines and provide evidence-based recommendations tailored to your situation.
Would you like me to provide a new response once I have access to the appropriate prostate cancer guidelines to properly address your question?
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Source Guidelines
NCCN Guidelines for Patients: Prostate Cancer (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with treatment for Prostate Cancer patients
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: